key: cord-1051523-ylsdj7vn
authors: Interiano, Cristina; Muze, Sheicho; Turner, Brian; Gonzalez, Mark; Rogers, Beverly; Jerris, Robert; Weinzierl, Elizabeth; Elkhalifa, Mohamed; Leung-Pineda, Van
title: Dataset for Longitudinal Evaluation of the Abbott ARCHITECT SARS-CoV-2 IgM and IgG Assays in a Pediatric Population Divided by Age
date: 2021-04-30
journal: Data Brief
DOI: 10.1016/j.dib.2021.107110
sha: 993656ba1b5d3e8d35c92458bfa3c11078e2f2ff
doc_id: 1051523
cord_uid: ylsdj7vn

BACKGROUND: SARS-CoV-2 infection in children does not seem to follow the same pattern as in adults. Limited information is published on the level of antibody production and the duration of antibody response in children with COVID-19. Moreover, it is unknown if all children have a similar immune response to the infection, or if there are age dependent differences. In this data, we look at the IgM and IgG levels and duration of two age groups infected by the SARS-CoV-2 virus. METHODS: Residual laboratory specimens from pediatric patients positive for SARS-CoV-2 infection were tested for IgM and IgG against SARS-CoV-2 using an automated Abbott ARCHITECT i1000. We tested 181 specimens from 41 patients with a positive molecular result. Data was grouped either as time after nucleic acid amplification test (NAAT) or time after symptom onset. Patient samples were divided into 2 age groups: 0 to 11 years old and 12 to 19 years old. The assays detect IgM against the spike protein and IgG against the nucleocapsid protein.

Background: SARS-CoV-2 infection in children does not seem to follow the same pattern as in adults. Limited information is published on the level of antibody production and the duration of antibody response in children with . Moreover, it is unknown if all children have a similar immune response to the infection, or if there are age dependent differences. In this data, we look at the IgM and IgG levels and duration of two age groups infected by the SARS-CoV-2 virus.

Methods: Residual laboratory specimens from pediatric patients positive for SARS-CoV-2 infection were tested for IgM and IgG against SARS-CoV-2 using an automated Abbott ARCHITECT i1000. We tested 181 specimens from 41 patients with a positive molecular result.

Data was grouped either as time after nucleic acid amplification test (NAAT) or time after symptom onset. Patient samples were divided into 2 age groups: 0 to 11 years old and 12 to 19 years old. The assays detect IgM against the spike protein and IgG against the nucleocapsid protein.

This is unpublished data co-submitted with the following research article: Table   Subject Health and medical sciences, Laboratory Medicine

Type of data 

The data shows the IgM and IgG results from residual COVID-19 positive patient samples. symptoms. Each figure divides the patient into two groups based on their age.

In Figure 1A , the results for IgM tests (y-axis) are plotted against the time (x-axis) when the specimens were collected after a positive molecular SARS-CoV-2 test for samples from patients 0 to 11 years old. The y-axis is the numerical result from the automated instrument and is in logscale to encompass the range of results. The orange line represents the cutoff of the assay (1.00).

The x-axis is divided in the following categories: 0-7 days, 8-14 days, 15-30 days, 31-60 days, 61-90 days, 91-120 days and > 120 days after positive molecular results. The black horizontal bars for each time group represent the median value of IgM results for that particular time group.. In Figure 1B , the results for IgG tests (y-axis) are plotted against the time (x-axis) when the specimens were collected after a positive molecular SARS-CoV-2 test for samples from patients 0 to 11 years old. The y-axis is in normal scale and the orange line represents the cutoff of the IgG assay (1.4) . The x-axis time groups are the same as Figure 1A . The black horizontal bars represent the median value of IgG results for that particular time group. Figure 1C is similar to Figure 1A , except that the data comes from patients 12 to 19 years old. Figure 1D is similar to Figure 2C shows the post symptom IgM data for the 12-19 year old group. Figure 2D displays the IgG data for the 12-19 year old group. Figure 2 represents data from 70 specimens from 15 patients for the 0-11 year old group and 86 specimens from 22 pediatric individuals for the 12-19 year old group. 

Specimens tested were leftover clinical blood samples from pediatric patients that tested positive for SARS-CoV-2 by a molecular method. Serial samples from patients were saved, when available, from April to November of 2020. Leftover specimens were stored at -20°C within 5 days from collection. Leftover specimens were stored at 4°C before transferring to frozen Tests used to detect IgM and IgG against SARS-CoV-2 were manufactured by Abbott Laboratories using the Abbott ARCHITECT i1000 (Abbott Park, IL) and used according to the manufacturer's instructions. Specimens were thawed at room temperature, aliquoted and centrifuged for 5 minutes at 3,000 X g before loading on to the instrument. The IgM assay

Longitudinal Evaluation of the Abbott Architect SARS-CoV-2 IgM and IgG Assays in a Pediatric Population. Accepted for publication to Practical Laboratory Medicine

The authors wish to thank Kevin Pannell and Wilfred Morales for collecting residual specimens and Randal Schneider for coordinating reagent procurement.

This study was supported by a grant from Abbott Laboratories.